Scientists confirm HIV capsid is a good drug target despite resistance, PgII

Key Highlights:

• In June 2025, the FDA approved lenacapavir, the first HIV capsid inhibitor, administered via injection every six months.
• Lenacapavir showed 100% effectiveness in preventing HIV infection in high-risk individuals during clinical trials.
• Research indicates that HIV can develop resistance to lenacapavir when it is used alone, but resistance mutations impair the virus's replication ability.
• The study confirms that the HIV capsid is a viable drug target, encouraging the development of new capsid-focused therapies.

Detailed Insights:

• The HIV capsid, which protects the virus's RNA, was identified as a potential drug target due to its essential and fragile nature.
• Lenacapavir's poor solubility, initially a drawback, was turned into an advantage, allowing for a slow-release, long-lasting injectable formulation.
• Resistance to lenacapavir primarily emerges when the drug is used as a monotherapy, highlighting the importance of combination therapies in HIV treatment.
• Drug-resistant viruses engineered in the lab showed significantly reduced replication rates, indicating a fitness cost associated with escaping lenacapavir.
• Targeting viral capsids may be a broader strategy applicable to other viruses beyond HIV, encouraging research into protective shells of viruses.

Key Concepts Involved:

• HIV Capsid: A protein shell that protects the virus's RNA and is essential for its ability to infect cells.
• Drug Resistance: The ability of a virus to evolve and become less susceptible to the effects of antiviral drugs.
• Combination Therapy: The use of multiple drugs simultaneously to suppress a virus and prevent the development of drug resistance.